BioAge Labs, Inc. BIOA
BioAge Labs, Inc. (Nasdaq: BIOA) is a cardio-renal-metabolic drug developer. Its lead program, BGE-102, is in Phase 2 for Cardiovascular/obesity-related (NLRP3 inhibitor). Its next catalyst on record is BGE-102: BioAge expects topline results from QUELL-DME Phase 2 trial in second half of 2027. (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BGE-102 — BioAge expects topline results from QUELL-DME Phase 2 trial in second half of 2027. (H2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BGE-102 | QUELL-CV dose-ranging proof of concept | small molecule | Phase 2 |
Recent results and decisions
- Oct 2, 2026started First participant dosed in QUELL-DME, a randomized three-arm Phase 2 trial (~180 participants) of oral BGE-102 alone or with anti-VEGF in DME; primary endpoint BCVA change at week 12.
BioAge Labs, Inc. (the “Company”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“DME”), and provided updates on the QUELL-DME Phase 2 tri
Filing - Aug 5, 2026started First participant dosed in QUELL-CV, a randomized Phase 2 dose-ranging trial of BGE-102 (30/60/90 mg vs placebo, ~160 adults, primary endpoint hsCRP change over 12 weeks).
In June 2026, BioAge announced that the first participant was dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102, its oral, brain-penetrant NLRP3 inhibitor, measuring inflammatory and cardiometabolic biomarkers
Filing - May 8, 2026positive Phase 1 topline (reported April 2026): median 86% hsCRP reduction at 60 mg and 120 mg once daily, 87-93% reached hsCRP <2 mg/L, no serious AEs
Across both 60 mg and 120 mg once-daily dose levels, BGE-102 achieved rapid and profound reductions in hsCRP, with median reductions of 86% from baseline, together with consistent reductions in IL-6 and fibrinogen.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.